$0.26
▲ +2.8% Today
as of Sep 4, 16:51 ET
Last 30 days
Recent Press Releases & News
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Mereo BioPharma and Sentynl Therapeutics Announce Option and License Agreement for alvelestat in Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD)
Overview
52-week range
$0.20
$2.37
3% of range
Avg surprise (last 3)
-116.7%
Avg reaction (last 2)
-3.0%
50% positive
Latest IV / EM
1030%
EM ±166.7% · $1 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.01 | — | — | — | — | financials |
| Tue May 12, 2026 | Mar/2026 | $-0.01 | $0.02 | -150.0% | +50.0% | +1.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.01 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.02 | $-0.01 | -100.0% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.02 | $-0.01 | -100.0% | — | -7.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.02 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.02 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.01 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.01 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | — | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.02 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | — | — | $0 | $500,000 | — | — | $0 |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-7M | $-9M | — | $-10M | $-10M | $-11M | — | $-9M |
| Net income | $-7M | $-7M | — | $-7M | $-15M | $-13M | — | $-15M |
| EPS (diluted) | $-0.01 | $-0.01 | — | $-0.01 | $-0.02 | $-0.02 | — | $-0.02 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $30M | $30M | $41M | $49M | $56M | $62M | $70M | $81M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $33M | $40M | $45M | $52M | $61M | $67M | $75M | $87M |
| Total assets | $35M | $41M | $46M | $54M | $63M | $68M | $76M | $89M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $6M | $7M | $5M | $7M | $8M | $8M | $15M | $16M |
| Total equity | $29M | $34M | $41M | $47M | $54M | $60M | $61M | $-73M |